Last updated: May 24, 2026
Hydrocortisone sodium succinate (HSC) is a widely used injectable corticosteroid. Supplier ecosystems differ by market (US, EU, APAC) and by product configuration (strength, container closure, sterile-manufacturing site, and labeled indication package). The most reliable way to identify true supply chain options is to anchor on FDA (Orange Book and FDA-licensed manufacturing), EU manufacturing authorizations (MAA/CEP where relevant), and each firm’s sterile injectable track record.
Which companies supply hydrocortisone sodium succinate injection in the US?
Answer: US market availability is typically dominated by generic sterile injectable manufacturers with FDA-approved abbreviated new drug applications (ANDAs) and licensed manufacturing sites producing sterile drug product.
US supply mapping to validate in procurement
For each candidate supplier, procurement due diligence should confirm:
- Product listing: NDA/ANDA identity for “hydrocortisone sodium succinate injection”
- Strength(s) and presentation(s) (commonly vial size and mg strength)
- Sterile manufacturing capability and site on the FDA label
- Distribution and lot release recordkeeping
- Current GMP compliance status for the specific sterile site
Orange Book anchoring for supplier eligibility
US “supplier” in practice means: the firm holding the ANDA/labeling right and the firm manufacturing and releasing product for the labeled presentation. For each strength/presentation, confirm Orange Book listing and the manufacturing site listed on the approved application.
What patents protect hydrocortisone sodium succinate and how do they affect supplier choices?
Answer: Hydrocortisone sodium succinate is an older, off-patent active ingredient. Supplier constraints generally come less from exclusivity and more from sterile injectable manufacturing capacity, batch release performance, and regulatory compliance.
Patent estate reality for broad sourcing
Procurement and licensing teams should expect:
- Limited or no active composition-of-matter exclusivity on the active ingredient
- Practical restrictions driven by:
- facility access
- sterile fill-finish contract capacity
- regulatory history (483s, warning letters, import alerts)
- ability to meet sterility assurance and container closure integrity
Are there FDA supply disruptions risks for hydrocortisone sodium succinate?
Answer: The biggest supplier risks are capacity bottlenecks and sterile manufacturing disruptions, not IP. Shortages often trace back to fill-finish constraints, container sourcing, or batch rejection rates.
Where risk shows up in buying committees
- lead time variability for specific vial presentations
- inconsistent availability across strengths
- lot-to-lot supplier changes for distributors
- cold-chain expectations (if any) by label and distributor logistics, even if the drug itself is typically handled under standard conditions
What generic forms of hydrocortisone sodium succinate are most commonly sourced?
Answer: Most purchasing targets are generic sterile injection formats with multiple vial presentations, sized for hospital emergency and inpatient protocols.
Presentation variants that change suppliers
- Strength and vial fill volume
- Container type (glass vial) and stopper/flip-off configuration
- Packaging (single carton vs bulk shipping configuration)
- Labeling format (US generic labeling, unit dose packaging differences)
How do sterile manufacturing constraints change the supplier list?
Answer: The pool of qualified suppliers narrows to firms that:
- own or contract sterile lyophilized/sterile reconstitution workflows if applicable to the product’s form
- have validated container closure systems for vials
- run routine sterility assurance and endotoxin controls with stable batch yields
Contract sterile manufacturing as a sourcing lever
Many “brand” or “label” holders outsource fill-finish. In practice, supplier selection should verify:
- who actually performs sterilization and fill-finish for the labeled product
- where batch testing and release occur
- whether the labeled manufacturer controls QC release or the contract manufacturer does
Which API suppliers make hydrocortisone sodium succinate raw material?
Answer: API is commonly produced through a global network of hormonals and steroid intermediates manufacturers. In most sterile injectable supply chains, the finished drug drug product manufacturer may buy API from one or more approved or qualified vendors.
API qualification checks procurement should run
- ASMF/DMF linkage for the API used in the ANDA/approved application
- supplier change control history
- impurity profile consistency vs the approved specifications
- ability to provide CoA, traceability, and batch certificates
How does EU sourcing compare with US sourcing for hydrocortisone sodium succinate?
Answer: EU supply is typically anchored by MAHs and parallel import/distribution channels, while US supply is anchored by FDA ANDA holders and labeled manufacturers.
EU-specific procurement validation
- marketing authorization holder (MAH) identity
- manufacturing sites authorized for the sterile drug product
- availability of GMP certificate for relevant sites where applicable
- whether product is imported and relabeled
What delivery systems and formulations affect supplier eligibility?
Answer: For hydrocortisone sodium succinate, the main formulation variable for supplier selection is the sterile injectable presentation that dictates fill-finish, container closure, and reconstitution workflow.
Supplier screening parameters
- container closure integrity validation
- particulate matter controls
- endotoxin and sterility test performance
- stability and shelf life under labeled storage conditions
What generic entry risks exist for hydrocortisone sodium succinate?
Answer: Risks are mostly operational, not legal. New entry risk is limited by sterile injectable regulatory and manufacturing complexity and by the economics of maintaining sterile capacity.
What can block new suppliers even when IP is gone
- inability to reliably meet sterility/quality release rates
- container/stopper procurement shortages
- fill-finish line constraints
- regulatory enforcement history at the manufacturing site
What to verify in supplier contracts for hydrocortisone sodium succinate
Answer: Contract terms should be built around supply continuity, batch release certainty, and regulatory traceability.
Contract clause checklist
- guaranteed lead times by strength/presentation
- lot replacement terms (reject or out-of-spec outcomes)
- right to audit manufacturing and QC release processes
- requirement to notify shortages, recalls, or deviations within defined SLAs
- change control notification for API source, sterilization method, or fill-finish sites
Key Takeaways
- Supplier selection for hydrocortisone sodium succinate injection is primarily constrained by sterile injectable manufacturing capacity and regulatory quality systems, not active IP.
- The practical “who supplies” list for any strength and presentation must be confirmed through FDA/Orange Book anchoring for US and authorized manufacturing sites for EU.
- Procurement risk centers on supply continuity: fill-finish constraints, batch rejection history, and lot release stability.
FAQs
- Which strength and vial presentations of hydrocortisone sodium succinate injection have the most limited supplier availability?
- How do I confirm the labeled manufacturer vs the actual sterile fill-finish contractor for hydrocortisone sodium succinate?
- What documentation should accompany hydrocortisone sodium succinate API and sterile drug product for audits?
- How can I anticipate shortages for hydrocortisone sodium succinate injection by monitoring manufacturing site signals?
- Do international (EU) suppliers translate into US availability via distributors, and how should procurement verify traceability?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-05-24).
- FDA. Drug Shortages. (Accessed 2026-05-24).
